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Abstract
Obesity is characterized by metabolic disorder and accompanying an altered and less diverse gut microbiota
composition during a fat-enriched diet. Recent studies indicated that sulphated polysaccharide prevents high-fat diet
(HFD) induced obesity, reduces metabolic disorder, and restores the gut microbiota. However, there are few studies
about Ulva prolifera polysaccharide (UPP) may induce anti-obesogenic effects. Therefore, the present study investigates
the enzymatic extracted UPP effects in HFD-fed mice. The results showed that UPP considerably slowed down the HFDinduced weight gain and improved metabolic disorders in HFD-fed mice. Notably, the effects were associated with
lower body weight gain, reduced adipose tissue hypertrophy, triglyceride concentration in liver and systemic low-grade
inﬂammation, and improved fasting blood glucose. Moreover, our result reveals that UPP may elevate the expression of
AMPK via adiponectin activation. Interestingly, we found that UPP may induce PPARa agonist to enhance b-oxidation
since the elevation of CPT-1 and PPARa expression simultaneously. Meanwhile, gut microbiota analysis revealed UPP
promoted the growth of Parasutterella, Feacalibaculum, and Biﬁdobacterium, and reduced the abundance of Acetatifactor, Tyzerella, Ruminococcus_1, and Desulfovibrio. The changes in microbiota may have a positively correlated effect
on improving obesity and metabolic abnormalities. UPP may prevent HFD-induced obesity and associated metabolic
diseases, as well as modulate the composition of gut microbiota to facilitate the growth of probiotics.
Keywords: Gut microbiota, Metabolic disorder, Obesity, Sulphated polysaccharide, Ulva prolifera

1. Introduction

O

besity and overweight are deﬁned as abnormal
or excessive fat accumulation that may lead to
harmful effects such as development of type II diabetes mellitus and cardiovascular disease [1]. These
conditions are also associated with body weight gain,
ectopic fat accumulation, adipocyte hypertrophy [2],
metabolic abnormalities [2], chronic inﬂammation
[2], insulin resistance [2], and gut microbiota diversity
alteration [3]. Due to the high costs and potentially

dangerous adverse effects of drugs, researchers have
become interested in identifying compounds derived
from natural products, such as algae, that may be
therapeutically effective in reducing obesity and
alleviating metabolic syndrome.
Marine green macroalgae, species of Chlorophyta
in the genus Ulva, are edible seaweeds with
numerous health-promoting bioactive components
[4]. Polysaccharides of algae are potential candidates
to reduce the impact of HFD on the occurrence of
metabolic disease. Ulvan is a type of sulphated
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polysaccharide and is mainly composed of rhamnose, uronic acids (glucuronic acid and iduronic
acid), and xylose [4]. Ulva prolifera polysaccharide
(UPP) is a soluble sulfated heteropolysaccharide [4]
that has recently been exploited for numerous applications. Previous studies have demonstrated that
UPP induced a potent improvement in glucose
metabolism in diabetic rats and adiponectin in adipose tissue and attenuation of nonalcoholic fatty
liver disease [5].
In short, UPP is the component most intensively
investigated for medical purposes. However, the
anti-obesity pharmacological effects of UPP have
been seldom studied. Thus, this study is designed to
clarify the molecular mechanisms involved in the
effects of enzymatic extracted UPP on lipid metabolism to gain an understanding of how these
polysaccharides might prevent obesity and modulate microﬂora in mice with diet-induced obesity.

2. Materials and methods
2.1. Reagents and chemicals
U. prolifera was obtained from East Green Biotech,
Inc. (Taitung, Taiwan). IL-6 and TNF-a) uncoated
enzyme-linked immunosorbent assay (ELISA) kits
were purchased from Thermo Fisher (Waltham,
MA, USA). ACC, anti-AMPK, anti-pAMPK, HSL,
anti-pHSL, and anti-b-actin were purchased from
Cell Signaling Technology (Beverly, MA, USA).
Anti-adiponectin, anti-CPT1A, anti-PPARa, and
anti-PPARg were purchased from Abcam (Cambridge, UK). Anti-IL-1b was purchased from Santa
Cruz Biotechnology, Inc. (Dallas, TX, USA). Total
dietary ﬁber assay kit was purchased from SigmaAldrich (St. Louis, MO, USA). Triglyceride Colorimetric Assay Kit was purchased from Cayman
Chemical (Ann Arbor, MI, USA). InnuPREP Stool
DNA kit was purchased form Analytic Jena
(Germany).
2.2. Ulva prolifera polysaccharide preparation
Polysaccharide extraction was according to the
total dietary ﬁber assay kit was purchased from
Merck & Co., Inc (Kenilworth, NJ, USA) instructions. Brieﬂy, 1 g of dried U. prolifera powder
was weighed into a beaker. Next, 50 mL of pH 6.0
phosphate buffer was added into the beaker. The
sample was gelatinized with 0.10 mL of heat-stable
a-amylase and then enzymatically digested with
50 mg/mL of protease and 0.10 mL of amyloglucosidase to remove the protein and starch present in
the sample, and incubated for 30 min at 60  C. Next,
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four volumes of 95% ethanol was then added to
precipitate the soluble dietary ﬁber. The solution
was placed at 4  C overnight to allow complete
precipitation.
2.3. Composition of sugar analysis
Sugar analysis was modiﬁed from methods previously described [6]. First, 1 mL of 2 N HCl/MeOH
was prepared and reacted with 3 mg of polysaccharide sample in a hydrolytic tube at 70  C for
8 h. HCl/MeOH was removed by vacuum. Next, the
sample was hydrolyzed with 2 mL of 2 N triﬂuoroacetic acid (TFA) in a sealed hydrolytic tube at
100  C for 1.5 h. TFA was removed by evaporation
under vacuum. The sugar compositions of polysaccharide were determined using HPAEC (Metrohm, Herisau, Switzerland). The column used was
a CarboPacPA1 column (Dionex, Sunnyvale, CA,
USA). An isocratic elution was performed at 1 mL/
min with 10 mM NaOH eluent containing 2 mM
Ba(OAc)2.
2.4. Animal experiments
Fifty-ﬁve 4-week-old wild-type C57BL/6J male
mice were purchased from NARlab (Taipei,
Taiwan). All experiments were approved by the
Institutional Animal Care and Use Committee
(NTU-108-EL-00098) of National Taiwan University.
Animals were co-housed with three to four mice per
cage
in
a
temperature-controlled
room
(22  C ± 2  C) on a 12 h light-dark cycle. The mice
were fed with a normal diet for one week to acclimate. After acclimatization, the mice were randomly
divided into 5 groups of 11 mice each into the
normal diet group (control, 13.5% of energy from fat;
LabDiet 5001, Fort Worth, USA) or HFD groups
(50% of energy from fat). The mice were supplemented daily with 100 mL normal saline (vehicle) or
100, 300, or 500 mg/kg of body weight polysaccharide (UPPL, UPPM, and UPPH, respectively)
by intragastric gavage. After 15 weeks, the mice
were fasted 8 h before and then euthanized by
carbon dioxide asphyxiation, and blood was withdrawn by cardiac puncture. Liver and adipose tissue
were immersed in liquid nitrogen and stored at
80  C for further analysis. Fasting blood glucose of
mice was measured at 8th week and 15th week,
respectively.
2.5. Biochemical analysis
The blood sample was withdrawn by cardiac
puncture in a tube containing 10 mL of heparin
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sodium under anesthesia at the end of experiment.
The blood centrifuged at 1000 g for 10 min at 4  C
and supernatant (serum) was collected. The serum
levels of AST, ALT, TC, TG, LDL, and HDL were
analyzed by the National Laboratory Animal Center
(Taipei, Taiwan).
2.6. Histopathological examination
Liver and adipose tissues were collected and
trimmed to 3e5 mm thickness. Trimmed sections
were ﬁxed in 10% paraformaldehyde, followed by
dehydration and parafﬁnization. Formalin-ﬁxed
parafﬁn-embedded tissues were stained with hematoxylin-eosin (H&E) for morphological examination. Adipocyte size and adipocyte number in
subcutaneous WAT was estimated using ImageJ
software (Rasband, W.S., ImageJ, U.S. National Institutes of Health, Bethesda, MD, USA).
2.7. Oral glucose tolerance test
Oral glucose tolerance test (OGTT) was performed in the 15th week. Animals were fasted 8 h
and weighed before measurement. The blood
samples were collected from the tail vein by cutting
off 2 mm of the tip with a sterile scalpel. The mice
were then treated with a glucose solution (2 g
glucose per kg mouse) by intragastric gavage. Afterward, the blood glucose level were monitored by
using a Onetouch glucometer (LifeScan, Inc., Milpitas, CA, USA) before and 30, 60, and 120 min
after the administration of the glucose solution. An
area under the curve (AUC) was calculated. AUC
between any two time points was calculated as
(Time difference in minutes between sequential
reads)*(Glucose level 1st time point þ Glucose
level 2nd time point)/2). The glucose level is
measured from the level at time zero to the end
time point level.

a and IL-6 were measured using ELISA kits according to the manufacturer's instructions.
2.9. Measurement of triglycerides in liver
Liver was homogenized with sterile phosphate
buffer and centrifuged at 1000 g for 30 min at 4  C.
Lipid was obtained from the homogenate. Next,
10 mL of sample was added to each well, followed by
150 mL of diluted Enzyme Mixture solution to
initiate the reaction. The plate was incubated for
15 min at room temperature. The absorbance was
measured at 530e550 nm using an ELISA reader.
2.10. Western blot analysis
Western blotting was performed according to our
earlier report [7]. Adipose tissues were homogenized
in an ice-cold lysis buffer (50 mM Tris-HCl, pH 7.4;
1 mM NaF; 150 mM NaCl; 1 mM EGTA; 1 mM phenylmethanesulfonyl ﬂuoride; 1% NP-40; and 10 mg/
mL leupeptin) for 1 h. Homogenates were then
centrifuged at 12000 g for 30 min at 4  C. Bio-Rad
protein assay (Bio-Rad Laboratories, Inc., Hercules,
CA, USA) was used to measure protein concentration.
2.11. Short-chain fatty acids analysis
SCFA quantiﬁcation was conducted as described
in a previous study [8]. SCFAs in fecal samples from
mice was extracted with 2-nitrophenylhydrazine (2NPH) at 60  C for 20 min. Potassium hydroxide was
added, and the samples were then heated for 15 min
after. After cooling, phosphoric acid was added to
the sample, and the sample was extracted with ethyl
ether. The upper organic layer was collected. A
SYNAPT G2-S high-deﬁnition mass spectrometer
(Waters MS Technologies, Manchester, UK) was
used for the SCFA quantiﬁcation in mice feces.
2.12. 16S rDNA gene sequencing and analysis

2.8. Measurement of cytokines
Whole blood was withdrawn by cardiac puncture
and centrifuged at 1000 g for 10 min and serum was
collected. Retroperitoneal fats were extracted using
sterile phosphate buffer and then centrifuged at
1000 g for 30 min at 4  C. The concentrations of TNF-

16s rDNA sequencing was modiﬁed from methods
previously described [9]. Fecal samples were stored
at 80  C. For gene sequencing, the puriﬁed DNA
was eluted using the innuSPEED Stool DNA kit
(Analytik Jena AG, Jena, Germany) according to the
manufacturer's protocol. The sample DNA quality

Table 1. The content of monosaccharide composition of Ulva prolifera polysaccharide.
Sample

UP

Molar ratio of monosaccharide composition (100%)
Rha

Gal

Glc

Xyl

Glc A

70.6 ± 29.7

2.04 ± 1.51

10.6 ± 6

12.4 ± 5.28

27.4 ± 9.22

Data are expressed as mean ± SD (n ¼ 3).
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Fig. 1. Effect of Ulva prolifera polysaccharide on epididymal white adipose tissue and liver in high-fat diet-fed mice. A) Representative images
of visceral fat pads (epididymal white adipose tissue) from each group of mice are shown at the end of week 15. Perigonadal, retroperitoneal, and
mesenteric fat pad, respectively, are depicted. B) Visceral fat pad weights were measured after 15 weeks of treatment. C) Visceral adiposity index (%)
was calculated as {[perigonadal þ mesenteric þ retroperitoneal fat pad weight (g)]/BW (g) * 100}. D) Representative images of hematoxylin and eosin
(H&E)-stained perigonadal fat pads of mice in each group. Scale bar, 100 mm. Data are expressed as mean ± SD (BeC, n ¼ 11 mice/group). E)
Adipocytes size in visceral adipose tissue was determined by Image J. F) Hepatic triglyceride levels. Scale bar, 100 mm. Data are expressed as
mean ± SD (C, n ¼ 8 mice/group). The statistical signiﬁcance of differences among the ﬁve groups were analyzed by one-way ANOVA and Duncan's
multiple range tests. The values with different letters (aed) are signiﬁcantly different ( p < 0.05) between each group.
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Table 2. The effect of UPPs on body weight, body weight gain, food intake, and food efﬁciency ratio.
Group

Control

HFD

UPPL

UPPM

UPPH

Initial weight (g)
Final weight (g)
Weight gain (g)
Food intake (g)
Food efﬁciency ratio (%)

18.41 ± 1.3a
26.74 ± l.7c
7.94 ± 1.3c
3.22 ± 0.3a
2.27 ± 0.3d

18.43 ± 1.1a
31.35 ± 3.4a
12.1 ±1.9a
2.41 ±0.2b
4.69 ± 0.7a

18.46 ± 0.9a
29.47 ± 1.5ab
9.95 ± 1.5b
2.32 ± 0.2b
4.01 ± 0.6b

18.46 ±1.2a
29.41 ±1.5ab
9.9 ± 1.7b
2.39 ± 0.3b
3.81 ± 0.6bc

18.43 ±0.9a
28.78 ± 2.8b
9.11 ± 2.5bc
2.48 ± 0.3b
3.41 ±0.9c

Food efﬁciency ratio (%) ¼ (daily weight gain/daily food intake)  100. Data are expressed as mean ± SD (n ¼ 11 mice/group). The
statistical signiﬁcance of differences among the ﬁve groups were analyzed by one-way ANOVA and Duncan's multiple range tests. The
values with different letters (aed) are signiﬁcantly different (p < 0.05) between each group.

was assessed by NanoDrop 1000 spectrophotometer
and sent to Biotools Co., Ltd., for 16S rRNA gene
ampliﬁcation, sequence library construction, and
sequencing. The PCR primer sequences were used to
amplify the V3eV4 regions of bacterial 16S rRNA.
The library DNA was sequenced using the Illumina
HiSeq 2500 platform and paired-end reads (250 bp)
were generated. Sequences were chimera-checked
and ﬁltered from the data set before the effective tags
were grouped by 97% DNA sequence similarity into
operational taxonomic units (OTUs).
2.13. Statistical analysis
Quantitative data are presented as mean ± standard deviation (SD). Statistical analysis was conducted with one-way analysis of variance (ANOVA)
using SPSS 12.0. A p-value less than 0.05 was
considered statistically signiﬁcant, and the Duncan's
multiple range post hoc test was applied if the pvalue was less than 0.05. Graphs were created using
SigmaPlot 12.5 software.

3. Results
3.1. Monosaccharide composition of Ulva prolifera
Hydrolyzed sample was analyzed and quantiﬁed
by high-performance anion exchange chromatography (HPAEC) system. UPP consisted of 70.6 ± 29.7%
rhamnose, 27.4 ± 9.22% glucuronic acid, 12.4 ± 5.28%
xylose, 10.6 ± 6.0% glucose, and 2.04 ± 1.51% galactose
(Table 1).

3.2. UPP reduced body weight in high-fat diet-fed
mice
At the end of the experiment, the mean body
weight of mice fed a HFD was 22.5% higher than the
control group, which demonstrated that HFD successfully induced weight gain in mice. Meanwhile,
mice fed a HFD with UPPL, UPPM, or UPPH
showed a signiﬁcantly reduced body weight gain,
with a 11.8, 12.0, and 16.2%, respectively, compared
with the HFD mice (Fig. S1 & Table 2), suggesting
that UPPs slowed down HFD-induced weight gain
in HFD-fed mice.
The food intake of the control group was signiﬁcantly higher than the HFD-fed group (Table 2) due
to the differences in dietary energy density.
Furthermore, the FER of the UPPL, UPPM, and
UPPH groups was reduced with increasing polysaccharide concentration, while the FER of the HFD
group was two times higher than that of the control
group (Table 3). These results indicate that the effect
of UPP on suppressing body weight gain was not via
changing food intake.
Serum biochemical parameters were analyzed to
evaluate the impact of UPP administered to the
HFD-fed mice. Furthermore, an additional of
cholesterol (0.5%) was added into the HFD to promote the development of lipid disorder. As the results in Table 3 demonstrate, TC and LDL-C levels
were signiﬁcantly higher in the HFD group than
control group after animal were fed a HFD for three
months. Subsequently, TC and LDL-C levels

Table 3. Effect of UPPs on serum biochemical parameters in high-fat diet-fed C57BL/6 mice.
Item

Control

HFD

UPPL

UPPM

UPPH

AST (U/L)
ALT (U/L)
TC (mg/dL)
TG (mg/dL)
HDL-C (mg/dL)
LDL-C (mg/dL)
HDL/LDL
AI (TC/HDL-C)

95.4 ± 32.6a
15.3 ± 1.9ab
42.2 ± 5.4d
27.9 ± 5.5a
36.6 ± 4.1b
4.7 ± 0.4d
7.6 ± 0.7a
1.2 ± 0.1a

99.3 ± 26.0a
14.7 ± 1.5ab
101.5 ± 8.8a
30.9 ± 15.7a
79.1 ± 5.4a
30.4 ± 4.5a
2.7 ± 0.5c
1.3 ± 0.1b

95.0 ± 38.8a
12.9 ± 2.0b
93.4 ± 8.1ab
28.6 ± 6.8a
73.8 ± 5.2a
25.2 ± 3.0b
2.7 ± 0.3c
1.3 ± 0.1b

83.0 ± 42.2a
17.9 ± 3.2a
94.6 ± 12.3ab
27.0 ± 8.2a
77.0 ± 9.0a
25.6 ± 3.8b
3.0 ± 0.2bc
1.3 ± 0.1b

74.2 ± 45.1a
18.0 ± 3.4a
88.2 ± 11.9c
25.0 ± 5.9a
75.6 ± 6.8a
21.1 ± 3.6c
3.4 ± 0.3b
1.2 ± 0.1a

Data are expressed as mean ± SD (n ¼ 7e8 mice/group). The statistical signiﬁcance of differences among the ﬁve groups were analyzed
by one-way ANOVA and Duncan's multiple range tests. The values with different letters (aed) are signiﬁcantly different (p < 0.05)
between each group. AI ¼ atherogenic index.
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Fig. 2. Effect of Ulva prolifera polysaccharide on fasting blood glucose, glucose tolerance, and cytokine in high-fat diet-fed C57BL/6 mice. A)
Fasting blood glucose on week 8th and B) week 15th. C) Oral glucose tolerance test and D) the corresponding area under the curve. E) Serum tumor
necrosis factor a (TNF- a) and F) visceral adipose tissue interleukin 6 (IL-6) levels were analyzed by enzyme-linked immunosorbent assay. G) Protein
levels of interleukin -1b (IL-1b) in visceral adipose tissues were analyzed by western blot; H) IL-1b protein was quantiﬁed using b-actin as the
loading control. Data are expressed as mean ± SD (AeD, n ¼ 7e8 mice/group). The statistical signiﬁcance of differences among the ﬁve groups were
analyzed by one-way ANOVA and Duncan's multiple range tests. The values with different letters (aed) are signiﬁcantly different ( p < 0.05) between
each group.

52

JOURNAL OF FOOD AND DRUG ANALYSIS 2022;30:46e61

ORIGINAL ARTICLE

presented a decreasing trend in the UPPL, UPPM,
and UPPH groups. TC levels in the UPPL, UPPM,
and UPPH groups were reduced by 8, 6.6, and
13.1%, respectively. In parallel, LDL-C levels were
statistically signiﬁcant reduced by 17.4, 15.8, and
30.6%, respectively. However, TC and LDL-C levels
in the UPPH group was signiﬁcantly lower than the
UPPL and UPPM groups after 15-week administration. Finally, the HDL-C levels in the intervention
groups had no statistical signiﬁcant difference
compared with that in the HFD group.
3.3. UPP reduced visceral fat pad mass and
prevented adipocyte hypertrophy in high-fat dietfed mice
The average weights of the perigonadal, mesenteric, and retroperitoneal WAT of the HFD group
was remarkably heavier than those of the control
group, while the visceral fat pad weights of mice in
the UPPL, UPPM, and UPPH groups tended to
decrease after 15 weeks of administration of UPP
(Fig. 1A, B). In addition, the inhibitory effects of
UPPH on HFD-induced elevation of fat pad weight
and visceral adiposity index were slightly higher
than those of UPPL and UPPM (Fig. 1B, C).
Furthermore, to evaluate the effect of UPP on
adipocyte morphology in HFD-fed mice, biopsy of
perigonadal fat pads was observed in a microscopic
view with H&E staining. It is clear from Fig. 1D that
larger and more hypertrophic perigonadal fat pads
in HFD-fed mice compared to mice in the control
group. The quantiﬁcation of adipocyte composition
is presented in Fig. 1E. In the HFD group, the percentages of adipocytes 5000e10,000 mm2 was 46.34%.
It was higher than those found in the UPPL, UPPM,
and UPPH group, which were 24.07, 10.00, and
2.97%, respectively. Moreover, UPP treatment at
high dose in the HFD group had a lower but similar
of <2500 mm2 adipocyte distribution (70.29%)
compared to control group (87.00%). Collectively,
the results showed that UPP limits the accumulation
of WAT, as smaller adipocytes were found in UPPtreated mice compared to HFD-fed mice.

normal histology in control group with no lipid
accumulation. In contrast, HFD-fed mice exhibited
numerous fat vacuoles in the HFD group, indicating
that the mice developed a high degree of macrovascular steatosis induced by HFD. Marked effects
were not observed for suppression of steatosis by
15-week ministration of low dose polysaccharide.
However, hepatocyte hypertrophy and hepatic
steatosis in mice fed an HFD, which was alleviated
after the UPPM and UPPH intervention. These
ﬁndings suggest UPP mitigated steatosis in an HFDinduced obesity mouse model (Fig. S2B). In addaction, TGs are strongly associated with non-alcoholic
fatty liver disease; therefore, hepatic TG levels were
compared among the groups. As shown in Fig. 1F,
the HFD group had a signiﬁcant increase in TG
levels (218.81 ± 32.7 mg/g) compared to the control
group. Meanwhile, the TG levels in the UPPL,
UPPM, and UPPH groups were reduced by 15.1,
35.6, and 46.4%, respectively. UPP therefore
ameliorated HFD-induced fatty liver.
3.5. UPP maintained blood glucose homeostasis in
high-fat diet-fed mice
There was a signiﬁcant increase in fasting blood
glucose (FBG) in the HFD group (Fig. 2A,B), which
meant that hyperglycemia was established successfully by obesity. The FBG was lower in the UPPH
group after eight weeks of treatment, but FBG levels
in the UPPL and UPPM groups were not signiﬁcantly different compared to the HFD group.
Notably, the hyperglycemic state of HFD-fed mice
in the UPPL, UPPM, and UPPH groups was
ameliorated after 15 weeks of polysaccharide
administration. The effect of UPP on glucose tolerance in HFD-fed mice is shown in Fig. 2C, D.
Moreover, there was an apparent low glucose
tolerance in HFD-fed mice. In contrast, the AUC of
mice administered UPPL and UPPM was signiﬁcantly improved compared with HFD-fed mice, and
UPPH reversed the effect back to the level observed
in the controlled. In short, UPP exhibited a potential
ability to modulate blood glucose levels.

3.4. UPP possessed hepatoprotective effects in highfat diet-fed mice

3.6. UPP suppressed inﬂammation in high-fat dietfed mice

Livers morphological analysis demonstrated that
the livers of mice in the control group were bright
red in color, while yellowish and dull fatty livers
were observed in HFD-fed mice (Fig. S2A). This
effect might be due to lipid accumulation. Next, liver
tissue was conﬁrmed in histopathological observations by H&E staining. Liver H&E demonstrated

A tremendous augmentation in serum TNF-a levels
was observed in the HFD group (2.03 ± 0.49 pg/mL)
(Fig. 2E): levels were increased 3-fold compared to the
control group (0.67 ± 0.19 pg/mL). Strikingly, highdose polysaccharide administration signiﬁcantly
decrease the serum concentration of pro-inﬂammatory cytokine TNF-a to 0.69 ± 0.41 pg/mL. The
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Fig. 3. Effect of Ulva prolifera polysaccharide on lipogenic protein expression in high-fat diet-fed C57BL/6 mice. Western blot analysis of
proteins involved in lipid metabolism in visceral adipose tissues. The proteins analyzed are involved in adiponectin, phosphorylated 50 AMP-activated
protein kinase (p-AMPK)/AMPK), adipogenesis (peroxisome proliferator activated receptor g [PPARg], CCAAT), lipogenesis (acetyl-CoA carboxylase
[ACC], Sterol regulatory element-binding protein 1c [SREBP1c]), lipolysis (hormone-sensitive lipase [HSL]), and b-oxidation (peroxisome proliferator
activated receptor a (PPARa); carnitine palmitoyltransferase-1 [CPT-1]). For quantiﬁcation of protein expression by western blotting, b-actin was
used as the loading control. Data are expressed as mean ± SD (n ¼ 7e8 mice/group). The statistical signiﬁcance of differences among the ﬁve groups
were analyzed by one-way ANOVA and Duncan's multiple range tests. The values with different letters (aec) are signiﬁcantly different (p < 0.05)
between each group.
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evidence strongly demonstrated that high dose of
UPP inhibited the basal release of TNF-a in HFD-fed
mice. However, there was no statistically signiﬁcant
difference was detected between UPPL group
(1.67 ± 0.32 pg/mL) and HFD group (2.03 ± 0.49 pg/
mL). Furthermore, the levels of visceral fat pad IL-6
and IL-1b were tested (Fig. 2FeH). The results
showed that HFD-fed mice produced higher levels of
IL-6 and IL-1b without UPP intervention. Low-dose
UPP did not have any apparent effect on levels of
these cytokines, but medium- and high-dose UPP
altered the IL-6 and IL-1b expression, resulting in
expression levels closer to the control group. These
results indicated that UPP could reduce low-grade
inﬂammation in HFD-fed mice in serum and adipose
tissue.
3.7. UPP might activate AMPK in high-fat diet-fed
mice by increasing adiponectin expression
Previous studies have suggested that adiponectin
could decrease hyperglycemia, as ectopic lipid
accumulation was rescued and sustained weight
loss without affecting food intake was observed after
replenishment with recombinant adiponectin in
mice [10]. As stated above, the body weight gain and
visceral fat pad weight of the treatment groups were
lower than those of the HFD group (Fig. 1 & Table
2). To test the hypothesis that adiponectin played a
role in these effects, adiponectin expression was
tested. We found that treatment with UPP led to a
dose-dependent increase in adiponectin expression
in adipose tissue (Fig. 3A, B). This analysis also
indicated that the HFD group had the lowest adiponectin level and the adverse effect was reversed
signiﬁcantly by treatment with UPPM and UPPH.
Next, based on a previous study by Yamauchi and
colleagues [11] reporting that the effects of adiponectin require AMPK activation. As shown in
Fig. 3C, compared with the control group, UPPM
and UPPH treatment effectively enhanced phosphorylation of AMPK, with a 1.5-fold increase in
phosphorylated AMPK in these groups compared to
the control, HFD, and UPPL groups.

suppressed effectively in the presence of high-dose
UPP. C/EBPb is expressed early during adipogenesis and is also required along with PPARg for
robust adipocyte-speciﬁc gene expression [13]. As
shown in Fig. 3E, no signiﬁcant differences in the C/
EBPb expression level were observed in the control,
HFD, and UPPL groups, but treatment with UPPM
and UPPH attenuated the expression of C/EBPb.
As shown in Fig. 3H, compared with the control
group, phosphorylation of ACC was effectively
enhanced with UPP treatment. This result indicated
that AMPK phosphorylates ACC to inhibit enzyme
activity, leading to downregulation of lipogenesis.
Moreover, HFD signiﬁcantly reduced SREBP-1c gene
expression, and UPPL had no apparent effect on this
(Fig. 3I). In contrast, SREBP-1c gene expression was
higher in the UPPM and UPPH groups than in the
HFD group, indicating that UPP suppressed SREBP1c processing and thereby prevented the feed-forward transcription of their own genes.
Daval et al. observed that activation of AMPK
could increase HSL phosphorylation in adipocytes
and translocation to the lipid droplet was inhibited
[14]. As shown in Fig. 3J, K, p-HSL was downregulated in the HFD group, while its levels were
increased in the HFD-fed mice treated with UPPM
and UPPH.
Shuttling esters of fatty acids into the mitochondria
is accomplished through an acyl-carnitine intermediate, which itself is generated by the action of the
CPT-1 enzyme for b-oxidation [15]. The expression of
CPT-1A was signiﬁcantly lower in HFD-treated mice
compared with those in the control group (Fig. 3M).
Surprisingly, UPP administration increased CPT-1A
expression, rebalancing the dysregulated lipid
metabolism in adipocytes. PPARa is a master regulator of genes involved in triglyceride metabolism,
particularly b-oxidation [16]. As shown in Fig. 3N, the
protein level of PPARa was increased up to 2-fold in
the UPPM and UPPH groups compared to the HFD
group. In contrast, PPARa expression was not
signiﬁcantly different in the control and UPPL
groups compared to the HFD group. In short, upregulation of PPARa protein level may further stimulate CPT-1A expression to enhance b-oxidation.

3.8. UPP exerted anti-obesogenic effects by
regulating lipogenic protein expression in high-fat
diet-fed mice

3.9. UPP modulated the high-fat diet-induced gut
dysbiosis

Activation of AMPK associated with suppression
of adipogenic differentiation was validated by Chen
et al. [12]. Therefore, we aimed to determine the
effect of UPP on adipogenesis. PPARg expression
showed the greatest increase in HFD-fed mice
(Fig. 3D, F). Notably, the expression of PPARg was

To investigate whether the concentration of
SCFAs was affected by polysaccharide concentration, we chose to compare SCFA concentration in
the UPPL and UPPH groups. UPP administration
signiﬁcantly increased the levels of acetate (Fig. 4A)
and propionate (Fig. 4B) compared to the HFD-fed
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Fig. 4. Effect of Ulva prolifera polysaccharide on short-chain fatty acid concentration and gut microbiota composition analysis. A) Acetate, B)
propionate, and C) butyrate were quantiﬁed in the colons of chow-fed and high-fat diet (HFD)-fed mice after 15 weeks of treatment. D) Partial least squares
discriminant analysis (PLS-DA) demonstrates distinct colon microbial composition in the different groups. Each data point represents one sample and each
color represents each group (percent variation explained by each PLS is shown in parameters). E) 16s rRNA gene sequencing analysis of colon contents at
the phylum level. F) Variability in the Firmicutes/Bacteroidetes ratio in the gut microbiota. G) Box plot of 16s rRNA gene sequencing analysis of colon
contents at the genus level. Data are expressed as mean ± SD. The statistical signiﬁcance of differences among the ﬁve groups were analyzed by one-way
ANOVA and Duncan's multiple range tests. Symbols indicates signiﬁcant differences compared to the HFD group, *p < 0.05; **p < 0.01.
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Fig. 4. (Continued)

group. In contrast, the difference in levels of butyrate was not signiﬁcant between the groups
(Fig. 4C). However, the acetate, propionate, and
butyrate concentration were not signiﬁcantly
different between the UPPL and UPPH groups.
Next, we analyzed the effects of UPP intervention
on the gut microbiota composition in the colon.
PLS-DA revealed distinct clustering of microbiota
composition for each treatment group (Fig. 4D). At
the phylum level, HFD induced an increase in the
abundance of Firmicutes and Proteobacteria, but a
decrease in Bacteroidetes (Fig. 4E). Obese mice
demonstrated an increase in F/B ratios; however, no
dose-dependent improvement in this ratio was
observed as UPP doses increased (Fig. 4F).
In addition, the results showed that the abundances of pathogenic Acetatifactor and Tyzzerella,
were higher in HFD group (Fig. 4G). They had been
found to be signiﬁcantly increased with systemic
inﬂammation in HFD [17]. Further statistical analysis demonstrated that the HFD group had signiﬁcantly higher abundances of Desulfovibrio and
Ruminoccoccus_1. Inability to regulate levels of
Desulfovibrio and Ruminoccoccus_1 in obese individuals has been associated with metabolic disorder and increased body adipose mass [18]. UPP
supplementation remarkably decreased the abundance of Acetatifactor, Tyzzerella, Desulfovibrio, and
Ruminoccoccus_1 in HFD-fed mice. In addition,
compared to the HFD group, UPPM intervention
resulted in enrichment of the abundances of Parasutterella, Faecalibaculum, and Biﬁdobacterium. It has
been shown that Parasutterella and Faecalibaculum
might possess an anti-obesity effect [19] and lead to
an increase in levels of Biﬁdobacteria, which are
depleted in inﬂammatory diseases and promote gut
health [20].

4. Discussion
The dosages of the UPP were chosen based on
studies that indicated that 300 and 500 mg/kg of
sulphated polysaccharide from sea cucumber and
Paciﬁc abalone could ameliorate obesity [3,21]. In
this study, we showed that body weight, body fat,
and metabolic syndrome parameters were
improved after intervention with UPP, as soluble
ﬁber may affect lipid absorption. Furthermore, it has
been shown that the water-holding capacity of
polysaccharide is higher than insoluble ﬁber, and
that a viscous solution was created within the
gastrointestinal tract that could cause gastroparesis
to create a postprandial satiety effect [22]. The
digestion process was slowed down, and this might
decrease the food intake. However, there was no
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signiﬁcant difference in food intake between the
HFD and treatment groups. This indicated that the
higher energy density in the HFD group slowed
down gastric emptying, prompting a lower food
intake in this group.
In the study, we expected liver injury by HFD, but
serum AST and ALT concentration no signiﬁcant
differences were observed between control and
HFD groups. AST concentration did not vary
signiﬁcantly among control, HFD, and the UPP
supplemented HFD groups. Intriguingly, the HFDfed mice fed a medium and high dose UPP had a
signiﬁcantly higher ALT concentration to the UPPL
group. Atherogenic index (AI) is a novel indicator
involved in dyslipidemia [23]. An elevated of TC,
LDL-C, and AI are the factors for the development
of many lipid-related diseases such as atherosclerosis, cardiovascular disease and obesity. Moreover,
study found that HFD induced hyperlipidemia in
rats, results in a remarkable increase in serum TC
and LDL-C. Treatment with UPP resulted in a
declined lipid proﬁle, such as TC and LDL-cholesterol, similar to the reference.
Adiponectin has recently been indicated as a
treatment for obesity-associated metabolic syndromes. Yamauchi and colleagues indicated that the
effects of adiponectin require AMPK activation [11].
Undeniably, AMPK plays an important role in
adipocyte homeostasis. Stimulating b-oxidation by
inhibiting ACC through phosphorylation via upregulation of adiponectin appeared to be primarily
mediated by the activation of AMPK [24]. Our
experiment demonstrated that the intervention of
UPP reduced fatty acid synthesis gene expression in
HFD-fed mice. SREBP is a key lipogenic transcription factor. Surprisingly, we found that SREBP-1c in
125 kDa gene expression was higher in the UPPM
and UPPH groups than in the HFD group. According to Li et al., AMPK directly stimulated phosphorylation of SREBP-1c to prevent its cleavage and
nuclear translocation, leading to reduced lipogenesis [25]. Moreover, we also assessed levels of
PPARa, a master regulator of genes involved in
triglyceride metabolism, particularly b-oxidation
[16]. Song et al. found that CPT-1A was induced 2to 3-fold by the addition of each PPARa ligand;
these PPARa agonists enhanced b-oxidation [26].
Our results suggest that UPP might increase the
expression of AMPK via adiponectin to effectively
modulate lipogenic gene expression in HFD-fed
mice.
Fiber reaches the colon undigested by human
digestive enzymes; however, it can be fermented by
colonic microﬂora that generate SCFAs. SCFAs
exert multiple effects on host metabolism and
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physiology, such as mediating anti-inﬂammatory
effects by inducing IL-10 secretion, stimulating insulin excretion, and lowering food intake [27]. It was
also reported that short-term oral SCFA intervention could alleviate diet-induced obesity and insulin
resistance in mice through activation of the adiponectin-mediated pathway [28]. Our results revealed
that the administration of UPP could increase the
SCFA concentration in the colons of HFD-fed mice,
especially acetate and propionate. Hence, we
conjecture that acetate and propionate exert antiobesity effects by stimulating the expression of
adiponectin in adipose tissue.
Alterations in the phyla Firmicutes and Bacteroidetes were described in obese animals, and
increased levels of Firmicutes and decreased levels
of Bacteroidetes have been associated with obesity
and metabolic disorders [29]. The Firmicutes/Bacteroidetes ratio has been considered a hallmark for
obesity. However, Schwiertz and his collogue did
not observe any modiﬁcations or even reported
decreased Firmicutes/Bacteroidetes ratios in obese
animals and humans [30]. Interestingly, MendezSalazar and colleagues found that Proteobacteria was
substantially more abundant in the obese group and
that there was a positive correlation between Proteobacteria and fat consumption [31]. Meanwhile, the
relative abundance of Proteobacteria was 3% in mice
from the HFD group compare to control group
(1.87%) which is indicative of dysbiosis. Notably,
taxonomic proﬁling demonstrated that treatment
with UPPL, UPPM, and UPPH reduced the Proteobacteria phylum, with a 1.73, 1.61, and 2.05%,
respectively in HFD-fed mice. Intervention with
Enterobacter, a member of the Proteobacteria phylum,
in germ-free mice resulted in the development of
obesity and insulin resistance [32]. The abnormal
growth of Proteobacteria may be a marker of disease
risk. Besides, we observed an increase in Biﬁdobacterium in the colon after supplementation with
UPP. In fact, some studies demonstrated that animals fed with the Biﬁdobacterium showed suppression of weight gain, ectopic fat accumulation,
increased glucose tolerance, and a decrease in inﬂammatory diseases compared to placebo-treated
control animals [20].
In conclusion, the present study (Fig. S3) indicates
that UPP alleviates HFD-induced weight gain,
reduction in adipose tissue hypertrophy and triglyceride concentration in liver. These effects are
associated with mitigates of systemic low-grade
inﬂammation, and improves FBG and lipid metabolism. In addition, UPP may increase the acetate
and propionate concentration and improve gut
microbiota composition to maintain colonic health.

We suggest that oral administration with UPP represents potential prebiotic for ameliorate HFDinduced obesity and metabolic disorder.
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Supplementary Figures

Supplemtary Fig. 1. Effect of Ulva prolifera polysaccharide on body weight in high-fat diet-fed mice. Chow-fed and high-fat diet (HFD)-fed
mice were treated daily with normal saline or UPP (100, 300, or 500 mg/kg) for 15 weeks by intragastric gavage. A) Representative images of each
group of mice at the end of week 15 are shown. B) Average body weight and C) body weight gain were measured throughout the 15-week period. Data
are expressed as mean ± SD (n ¼ 11 mice/group). The statistical signiﬁcance of differences among the ﬁve groups were analyzed by one-way ANOVA
and Duncan's multiple range tests. The values with different letters (aec) are signiﬁcantly different ( p < 0.05) between each group.
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Supplementary Fig. 2. Effect of Ulva prolifera polysaccharide on hepatic steatosis in high-fat diet-fed mice. A) Representative liver images of
each group of mice are shown at the end of week 15. B) Representative images of hematoxylin and eosin (H&E)-stained liver tissue in each group of
mice.

Supplementary Fig. 3. Schematic diagram of molecular mechanisms by which Ulva prolifera polysaccharide exerts anti-obesity effects in
high-fat diet-fed mice. Administration of UPP to the high-fat diet-fed mice could prevent body weight gain, reduce metabolic disorder and
inﬂammation, regulate lipid metabolism in adipose tissue, and modulate the composition of the gut microbiota.
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